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Background: In this post-hoc analysis, rates of remission and recovery were evaluated in patients with
bipolar depression treated with lurasidone.
Methods: Outpatients meeting DSM-IV-TR criteria for bipolar I depression, were randomized to 6 weeks
of once-daily, double-blind treatment with lurasidone 20–60 mg, lurasidone 80–120 mg or placebo,
followed by a 6-month, open-label, ﬂexible-dose, lurasidone continuation study. Recovery was deﬁned as
meeting criteria for combined symptomatic remission (Montgomery–Asberg Depression Rating Scale
total score r12) and functional remission (all Sheehan Disability Scale domain scores r3) sustained for
at least 3 months in the 6-month continuation study.
Results: A signiﬁcantly higher proportion of lurasidone-treated patients met criteria for combined
symptomatic remission and functional remission (33.3%, 91/273) compared to the placebo group (21.0%,
30/143, po0.05, NNT¼9) at the 6-week study endpoint. In the 6-month continuation study, the pro-
portion of lurasidone-treated patients achieving sustained recovery was 60.7% (85/140) and 44.9% (31/
69), for patients who continued lurasidone treatment and who switched from placebo to lurasidone,
respectively.
Limitations: The deﬁnition of recovery used has not been previously validated and the analysis was post
hoc. Lack of a control group in the continuation study limits data interpretation.
Conclusions: Recovery in patients with bipolar depression was assessed based on rates of combined
symptomatic and functional remission sustained over time. A majority of patients initially treated with
lurasidone in the acute phase achieved recovery status in the continuation study. Treatment with lur-
asidone (vs. placebo) earlier in the course of the bipolar depressive episode increased the likelihood of
subsequent recovery.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bipolar disorder is a persistent, serious psychiatric illness with
an estimated prevalence of approximately 1% (Merikangas et al.,
2007). Major depressive episodes constitute the most common
symptomatic state associated with bipolar disorder (Judd et al.,
2002; Calabrese et al., 2004; Kupka et al., 2007), imposing a large
illness burden as well as substantial direct and indirect costs onB.V. This is an open access article u
., One Bridge Plaza, Suite 510,
oebel).patients, caregivers and society (Calabrese et al., 2004; Huxley and
Baldessarini, 2007; Fagiolini et al., 2013; Kleine-Budde et al., 2014).
In addition to the risks of suicide and poor symptomatic outcomes,
poor functional outcomes are common (Huxley and Baldessarini
2007; Jamison 2000; Leverich et al., 2003; Wingo et al., 2010).
Individuals with bipolar disorder are commonly unemployed or
disabled, despite having at least some college or post-high school
education (Wingo et al., 2010; Kupfer 2005; Simon 2003; Kogan
et al., 2004). Difﬁculties with work adjustment and global outcome
often persist after syndromic recovery from bipolar mood episode
(Strakowski et al., 1998; Tohen et al., 2000). Although associated,
functional recovery tends to lag substantially behind symptomatic
remission (Tohen et al., 2003a; Goldberg et al., 2005; Sheehan andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Ravelli, 2000; Simon et al., 2000).
Relatively little high-quality evidence exists to guide long-term
maintenance treatment for bipolar depression. Long-term ad-
junctive antidepressant treatment was not superior to use of a
mood stabilizer alone in a meta-analysis involving patients with
bipolar disorder (Ghaemi et al., 2008). Long-term antidepressant
treatment may increase the risks of treatment-emergent mania
and rapid cycling in patients with bipolar disorder (Ghaemi et al.,
2001; Strejilevich et al., 2011). Selected atypical antipsychotics
have demonstrated efﬁcacy in the treatment of acute bipolar de-
pression, particularly quetiapine in both immediate (Calabrese
et al., 2005; Thase et al., 2006) and extended-release formulations
(Suppes et al., 2014), and the combination of olanzapine plus
ﬂuoxetine (Tohen et al., 2003b). In contrast, the other atypical
antipsychotics aripiprazole and ziprasidone did not differentiate
from placebo in randomized acute bipolar I depression trials
(Thase et al., 2008; Lombardo et al., 2012; Sachs et al., 2011). More
recently, lurasidone has demonstrated efﬁcacy in improving de-
pressive symptoms, and enhancing function and quality of life,
both as monotherapy and adjunctive therapy to lithium or
valproate, for the treatment of depressive episodes associated with
bipolar disorder (Loebel et al., 2014a, 2014b; Citrome et al., 2014).
Recovery in patients with serious mental illness has generally
been deﬁned as sustained improvement in both symptom control
together with adequate global social/vocational functioning
(Sheehan et al., 1996, 2008; Sheehan and Sheehan, 2008; Mancini
et al., 2012; Frank et al., 1991; Robinson et al., 2004; Stahl et al.,
2010). However, there are few reports that examine rates of
combined symptomatic and functional remission in patients with
bipolar disorder over extended time periods. In the past, recovery
has been commonly conceptualized as sustained symptomatic
(rather than functional or both symptomatic and functional) re-
mission, as in the National Institute of Mental Health Collaborative
Study of Depression (Keller et al., 1983), the McLean-Harvard First
Episode project (Tohen et al., 2000, 2003a), and the Systematic
Treatment Enhancement Program for Bipolar Disorder (STEP-BD)
study (Perlis et al., 2006). Likewise, the International Society for
Bipolar Disorders (ISBD) Task Force recommended recovery be
deﬁned on the basis of symptom status (“remission”) and duration
(Tohen et al., 2009), rather than functioning. Using these criteria,
72% of 166 patients in the McLean-Harvard First Episode project
met symptomatic recovery criteria (Young Mania Rating Scale
score o5 and Hamilton Depression Rating Scale score o8 for at
least 8 weeks), as compared to only 43% achieving functional re-
covery (regaining both occupational level and residential status
held during the pre-intake year based on information from pa-
tients, family members, and medical records) by 2 years after in-
itial hospitalization for a DSM-IV manic or mixed episode. In the
STEP-BD study, 58.4% met recovery criteria (two or fewer thresh-
old-level symptoms of mood elevation, or depression for at least
8 weeks) within up to 2 years of follow-up (Perlis et al., 2006).
The primary objective of this post-hoc analysis was to evaluate
rates of sustained (for at least 3 months) recovery in patients with
bipolar depression treated with lurasidone for up to 6 months in
an outpatient continuation study.2. Methods
We conducted a post hoc analysis based on data from a pre-
viously reported double-blind, placebo-controlled trial in patients
with bipolar depression (Loebel et al., 2014a), that was followed by a
24-week, ﬂexible-dose, open-label continuation study of lurasidone
(Ketter et al., in press); these studies were conducted between April
2009 and February 2013. The studies were approved by aninstitutional review board at each investigational site and were
conducted in accordance with International Conference on Harmo-
nization Good Clinical Practices guidelines and with ethical princi-
ples of the Declaration of Helsinki. All patients signed an informed
consent document explaining study procedures and potential risks
before study entry.
2.1. Participants
This multiregional study, conducted in the United States and
7 other countries, enrolled outpatients, 18–75 years, diagnosed
with bipolar I disorder (with a history of at least one lifetime prior
bipolar manic or mixed manic episode) who were currently ex-
periencing a major depressive episode according to text revision of
the fourth edition of the Diagnostic and Statistical Manual of
Mental Disorders DSM-IV-TR criteria, of Z4 weeks but o12
months duration, with or without rapid cycling, and without
psychotic features. A Montgomery Asberg Depression Rating Scale
(MADRS) score of Z20 and a Young Mania Rating Scale (YMRS)
score of r12 were required at both screening and baseline. A
detailed summary of entry criteria and study design, as well as
results, are provided in the primary report (Loebel et al., 2014a).
2.2. Interventions
Eligible patients were randomized to receive 6 weeks of dou-
ble-blind treatment with lurasidone, at ﬂexible daily doses of ei-
ther 20–60 mg or 80–120 mg, or 6 weeks of placebo (PBO). Study
medication was taken once daily in the evening, with a meal or
within 30 min after eating. A total of 319 intent-to-treat patients
enrolled in the open-label, continuation study of lurasidone.
patients were started in the continuation study on open-label
lurasidone 60 mg/day with subsequent ﬂexible dosing to optimize
effectiveness and tolerability (between 20 mg/d and 120 mg/d), as
deemed clinically appropriate.
2.3. Outcomes
The MADRS is a ten-item clinician-rated assessment of severity
of depression, with higher scores associated with greater depres-
sion severity (Montgomery and Asberg, 1979). The Clinical Global
Impression of Bipolar Disorder-Severity (CGI-BP overall) is a sin-
gle-item clinician-rated assessment of overall bipolar illness se-
verity on a 7-point scale, with higher scores associated with
greater illness severity. The Sheehan Disability Scale (SDS) (Shee-
han et al., 1996) is a well-established, self-rated scale designed to
assess level of functional impairment across three major functional
domains, in which patients rate the extent to which (1) work,
(2) social life or leisure activities, and (3) home life or family re-
sponsibilities are impaired by mood symptoms on 10-point visual
analog scales (0¼Not at all, 1–3¼Mildly, 4–6¼Moderately, 7–
9¼Markedly, and 10¼Extremely), with higher scores reﬂecting
greater functional impairment. For our main analysis, we analyzed
MADRS, CGI-BP (overall), and SDS assessed at randomized acute
baseline, (Day 0), week 6 (end of randomized acute study), and
month 3 (week 19) and month 6 (week 32) of the continuation
study.
We deﬁned symptomatic remission as MADRS total score r12,
and functional remission as all SDS domain scores o3 (and/or SDS
mean domain score o3, representing no to at most mild func-
tional impairment) (Sheehan et al., 1996). We deﬁned “recovery”
in the continuation study as meeting criteria for both symptomatic
remission and functional remission sustained for at least 3 months
(2 consecutive visits at months 3 and 6). Sensitivity analyses were
performed using a MADRS score of o8 to assess rates of symp-
tomatic remission at speciﬁc time points as well as recovery.
Table 1
Baseline demographic and clinical characteristics.
Acute, double-blind study phase Continuation study
phase
Characteristic Lurasidone
(N¼323)
Placebo
(N¼162)
Lurasidone mono-
therapy (N¼316)
N % N % N %
Female 189 58.5 87 53.7 176 55.7
Race
White 213 65.9 107 66.0 215 68.0
Black/African–
American
46 14.2 21 13.0 39 12.3
Asian 46 14.2 28 17.3 39 12.3
Other 32 9.9 14 9.3 23 7.3
Mean SD Mean SD Mean SD
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In this post-hoc analysis, a logistic regression model was ap-
plied to evaluate the effect of lurasidone on attaining symptomatic
and functional remission and recovery. We built a parsimonious
prediction function for the likelihood of achieving recovery
(combined symptomatic and functional remission for at least
3 months), with respect to baseline and clinical characteristics, as
well as initial treatment response from the 6-week acute phase.
These characteristics included age, gender, duration of illness,
baseline (week-0 of the randomized acute phase) symptom se-
verity (CGI-BP overall), treatment received during the randomized
acute phase, and remission status for MADRS symptoms or SDS
function or both at week-6 of the randomized acute phase. The
performance and predictive accuracy of this multivariate function
was evaluated using c-statistics (D’Agostino et al., 2008).Age, years 41.7 12.3 41.2 12.4 42.0 12.6
Age of onset of
diagnosis,
years
27.7 11.4 27.4 10.8 27.7 11.4
Baseline scores (ITT population)
MADRS
Double-blind
baseline
30.5 5.0 30.5 5.0 30.1 5.0
Extension
baseline
14.8 9.4
CGI-BP Overall
Double-blind
baseline
4.5 0.6 4.4 0.6 4.5 0.6
Extension
baseline
2.8 1.2
ITT¼ intent to treat; MADRS¼Montgomery–Åsberg Depression Rating Scale; CGI-
BP-S¼Clinical Global Impression-Bipolar Version-Overall score.3. Results
Patient disposition is depicted in Fig. 1. Demographic and
clinical characteristics are summarized in Table 1. At week-6 (end
of the 6-week acute randomized phase), a signiﬁcantly higher
proportion of lurasidone treated patients met criteria for com-
bined symptomatic remission (MADRS total score ≤12) and func-
tional remission (all SDS domain scores ≤3 representing no to at
most mild functional impairment) (33.3%, 91/273 pooling the
LUR20-60 and LUR80-120 groups) compared to the placebo group
(21.0%, 30/143, po0.05, NNT¼9) (Fig. 2A). In a sensitivity analysis,
rates of combined symptomatic and functional remission using a
MADRS total score r8 and all SDS domain scores r3 were 24.9%
(68/273) and 14.0% (20/143) for lurasidone and placebo patients,
respectively, at the week-6 acute randomized phase endpoint
(po0.05, NNT¼10) (Fig. 2B).
The proportion of lurasidone treated patients attaining symp-
tomatic remission at week 6 of the acute randomized phase was
signiﬁcantly higher (40.9%, 132/323) compared to the placebo
group (24.7%, 40/162, po0.01, NNT¼7). Likewise, the proportion
of lurasidone treated patients attaining functional remission at
week 6 was signiﬁcantly higher (48.4%, 132/273) compared to the
placebo group (31.5%, 45/143, po0.01, NNT¼6). Lurasidone was
superior to placebo in achieving functional remission across the
3 SDS domains (SDS domain ≤3; Work/School, po0.05, NNT¼8;
Social Life, po0.001, NNT¼6; Family Life, po0.001, NNT¼5) at
week 6.Fig. 1. Patient disposition.
Fig. 2. Rates of combined symptomatic and functional remission at week 6 (LOCF).
*po0.05 (Lurasidone vs. placebo).In the 6-month, open-label, continuation study, the propor-
tions of lurasidone treated patients achieving recovery (meeting
criteria for combined symptomatic remission and functional re-
mission for at least 3 months), were 60.7% (85/140) and 44.9% (31/
69), in the LUR–LUR and PBO–LUR groups, respectively (p¼0.03,
NNT¼7) (Fig. 3A). There was also a signiﬁcant increase in the rate
of combined symptomatic and functional remission from week 6
(33.3% in the LUR–LUR group and 21.0% in the PBO–LUR group) to
week 32 (74.8% in the LUR–LUR group and 64.9% in the PBO–LUR
group at month 6 of the continuation study) (po0.001, trajectory
over time), that was independent of the treatment groups
(p¼0.798, treatment-by-time interaction).
Fig. 3. Rates of recovery *Po0.05 (LUR–LUR vs. PBO–LUR); LUR–LUR: Lurasidone
20–60 mg/d or 80–120 mg/d in the acute phase followed by lurasidone 20–120 mg/
d ﬂexibly dosed in the continuation study; PBO–LUR: placebo in the acute phase
followed by lurasidone 20–120 mg/d ﬂexibly dosed in the continuation study.
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6 using MADRS total score ≤8 and all SDS domain scores ≤3 for at
least 3 months were 45.7% (64/140) and 30.4% (21/69) for LUR–
LUR and PBO–LUR groups, respectively, at the month-6 continua-
tion study endpoint (po0.05, NNT¼7) (Fig. 3B).
The proportion of patients attaining sustained symptomatic
remission was 73.2% (112/153) for LUR–LUR patients and 66.6%
(50/75) for PBO–LUR patients in the 6-month continuation study
(Fig. 4A, p¼NS). The proportion of lurasidone treated patients
attaining sustained functional remission was 64.6% (95/147) for
LUR–LUR patients and 56.7% (42/74) for PBO–LUR patients in the
6-month continuation study (Fig. 4B, p¼NS).
A majority of patients (450%) achieved no more than mild
disability for the work, social life and family life domains (SDS
domain score r3) at both months 3 and 6 of the continuation
study in the LUR–LUR and PBO–LUR groups, with comparable
improvements in the SDS work/school, family life and social life
domains.Fig. 4. Rates of recovery (symptomatic and functional remission sustained for Z3
Months). LUR–LUR: lurasidone 20–60 mg/d or 80–120 mg/d in the acute phase
followed by lurasidone 20–120 mg/d ﬂexibly dosed in the continuation study;
PBO–LUR: placebo in the acute phase followed by lurasidone 20–120 mg/d ﬂexibly
dosed in the continuation study.Recovery (combined symptomatic and functional remission
sustained for at least 3 months) was associated with lower base-
line global bipolar illness severity (CGI-BP overall, p¼0.004) (as-
sessed at acute phase baseline) and non-white race (po0.001,
45.4% in white vs. 76.5% in non-white population), as well as lur-
asidone (rather than placebo) treatment received in the acute
randomized phase (p¼0.029). The proposed model had acceptable
calibration performance based on predictive accuracy (AUC ROC c-
statistics¼0.74). The week-6 remission status for symptoms
(MADRS total score ≤12) or functioning (all SDS domain scores ≤3)
or both predicted month-6 recovery (all p-values o0.001). The
bivariate analysis for recovery found that gender (recovery rate
was 64% in men vs. 49% in women) and duration of illness (mean
11 years in the recovery group vs. 14 years in the non-recovery
group, po0.05) were signiﬁcant predictors, but were not in-
dependent of race and baseline global bipolar illness severity.4. Discussion
We propose here that recovery in patients with bipolar dis-
order be deﬁned based on the attainment of both symptomatic
and functional remission, sustained over time. This is one of the
ﬁrst analyses in the bipolar disorder literature to apply a rigorous
deﬁnition of recovery (combined symptomatic and functional re-
mission sustained for at least 3 months) to a population of patients
undergoing long-term treatment for bipolar depression. We also
assessed rates of attainment of combined symptomatic and func-
tional remission at speciﬁc time points in this analysis.
Rates of combined symptomatic and functional remission in-
creased over time in lurasidone treated patients (LUR–LUR), from
33.3% at 6-weeks to 74.8% at the 6-month continuation study
endpoint. Using our recovery criteria (combined symptomatic and
functional remission sustained for at least 3 months), a total of
60.7% of patients treated continuously with lurasidone in the acute
and continuation studies (LUR–LUR) and 44.9% of patients treated
with placebo in the acute study followed by lurasidone in the
continuation study (PBO–LUR) achieved recovery; the between-
group difference was statistically signiﬁcant (NNT¼7). These
ﬁndings require conﬁrmation in future studies, but suggest that
initiation of lurasidone earlier rather than later in the course of an
acute depressive episode associated with bipolar disorder may
result in enhanced rates of recovery after longer-term treatment.
The ISBD task force recommended that recovery in patients
with bipolar disorder be deﬁned based on symptom severity and
duration (e.g. 8 consecutive weeks) alone, rather than including
functioning status (Tohen et al., 2009). The basis for this re-
commendation was that symptomatic and functional improve-
ment might not be synchronic or symmetrical (Tohen et al., 2009).
However, precisely because symptomatic remission and functional
remission are correlated (Bijl and Ravelli, 2000; Simon et al.,
2000), but do not necessarily coincide (Sheehan and Sheehan,
2008; Sheehan et al., 2008; Mancini et al., 2012; Tohen et al.,
2009), assessing them as separate outcomes could potentially fail
to recognize their interaction effects and the importance of at-
taining both of these recovery components (Sheehan et al., 1996,
2008; Sheehan and Sheehan, 2008). Indeed, if a perfect correlation
existed between symptomatic remission and functional perfor-
mance, there would be no need to consider them together. We
thus assessed symptomatic remission combined with functional
remission for at least 3 months as the key measure of recovery in
this analysis.
Our operationalized deﬁnition of recovery contrasts with prior
deﬁnitions that do not include a requirement for sustained
symptomatic remission and are less structured with respect to
functional recovery (e.g., “regaining individual premorbid levels of
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2000, 2009, 2012; Sachs et al., 2001). We believe that our pro-
posed operational criteria for recovery are both practical and
meaningful in that both symptomatic and functional status over a
sustained period of time are captured by these criteria. Sustained
symptomatic and functional improvements are key components of
full recovery that may be applicable across psychiatric disorders
(Sheehan and Sheehan, 2008; Sheehan et al., 2008; Mancini et al.,
2012; Tohen et al., 2009).
As recommended by the ISBD task force (Tohen et al., 2009),
both symptomatic and functional remission were also investigated
as separate outcomes in our analysis. A majority of the LUR–LUR
patients attained sustained functional and symptomatic remission
for at least 3 months (65% and 73%, respectively). Among patients
who met recovery criteria, improvements in the SDS work/school,
family life and social life domains were similar, suggesting that
lurasidone was effective across all domains of functional impair-
ment. Our ﬁndings are consistent with previous reports suggesting
that functional recovery is less common than symptomatic re-
covery in bipolar disorder patients (Tohen et al., 2000, 2003a,
2009; MacQueen et al., 2001), but in our study the absolute dif-
ference (8.6%) was relatively modest. Symptomatic and functional
recovery rates (26% and 24%, respectively) were similar in a 12-
month follow-up study of patients with bipolar disorder after
hospitalization for the treatment of a manic or mixed episode
(Keck et al., 1998). In contrast, there were marked differences
between symptomatic recovery (72%, having low total Young
Mania Rating Scale score r5 and Hamilton depression scale score
r8 for at least 8 weeks) and functional recovery (43%, regaining
both occupational level and residential status) 2 years after onset
of a ﬁrst manic/mixed bipolar episode in the McLean-Harvard First
Episode project (Tohen et al., 2003a).
Sustained recovery in the continuation study was more likely in
patients with lower acute baseline global bipolar illness severity
(CGI-BP overall), non-white race, and taking lurasidone (rather
than placebo) during the randomized controlled acute phase.
These ﬁndings are consistent with those observed in previous
studies involving patients with bipolar disorder (Gitlin et al., 1995;
Coryell et al., 1998; Tohen et al., 2000; Goldberg and Harrow, 2004,
2005, 2011).
Symptomatic remission and/or functional remission status at
week 6 (end of the acute treatment phase) was strongly and sig-
niﬁcantly related to the attainment of recovery at the subsequent
week 32 continuation study endpoint. The association between
remission status at week 6 (end of acute treatment phase) and
recovery at week 32 reafﬁrms the relationship of acute phase
treatment response to long-term treatment efﬁcacy and outcome
in bipolar disorder (Goldberg and Harrow, 2004, 2005, 2011;
Ketter et al. 2006; Berk et al., 2011). The lower recovery rate
among whites compared to other races is somewhat inconsistent
with existing ﬁndings (Tohen et al., 1990; Gonzalez et al., 2010),
and warrants further investigation. Shorter illness duration was
associated with symptomatic and functional remission and re-
covery. These results are consistent with prior ﬁndings showing
that a shorter illness duration since an initial mood episode pre-
dicted better functioning in bipolar disorder patients (Keck et al.,
1998; Tohen et al., 2000; Wingo et al., 2010). Gender differences in
recovery rate and illness duration were not signiﬁcant after ad-
justing for baseline severity and race.
4.1. Limitations
Several limitations of this analysis should be noted. The deﬁ-
nitions of symptomatic and functional remission and recovery
used in this analysis have not been previously validated and the
analysis was post hoc. Although the SDS is a well-validatedmeasure of disability and functional impairment in patients with
bipolar and other psychiatric disorders (Leon et al., 1997; Arbuckle
et al., 2009), it does not assess functional capacity in the same
objective and comprehensive manner as more recently developed
measures of functional impairment such as the Functioning As-
sessment Short Test (FAST) (Rosa et al., 2007) or the University of
California at San Diego Performance-Based Skills Assessment
(UPSA) (Mausbach et al., 2010). However, SDS total score was
highly signiﬁcantly correlated with FAST, total score (correlation
r40.74), and SDS work domain score correlated signiﬁcantly with
FAST occupational functioning (r¼0.74) in patients with bipolar
disorder (Suominen et al., 2015). Another limitation derives from
the lack of inclusion of a measure of neurocognitive performance
in the parent studies. Therefore, the relationship between change
in neurocognition and recovery could not be assessed here (Wingo
et al., 2009; Harvey et al., 2010). Importantly, the interpretation of
our ﬁndings is limited by the absence of a control group in the
continuation study. Since only patients with bipolar I depression
were enrolled, the extent to which ﬁndings of the study can be
generalized to patients with bipolar II depression warrants further
investigation. Study entry criteria that excluded patients with
serious psychiatric or medical comorbidity and active suicidal
ideation or behavior, reduced the generalizability of the results.5. Conclusions
In this post hoc analysis, recovery in patients with bipolar de-
pression treated with lurasidone was assessed based on rates of
sustained symptomatic and functional remission after a 6-week
acute phase followed by a 6-month continuation study. A majority
of lurasidone-treated patients achieved recovery status in the
continuation study. Treatment with lurasidone (vs. placebo) earlier
in the course of the bipolar depressive episode increased the
likelihood of subsequent recovery. Our criteria for recovery and
predictors of recovery in patients with bipolar disorder warrant
further investigation and validation in future studies.Role of funding source
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